Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia.
Lynette CheeNora LeeAndrew GriggMelissa ChenAnthony SchwarerJeffrey SzerSumita RatnasingamSonia RajPohan LukitoDavid YeungTimothy HughesNaranie ShanmuganathanPublished in: Internal medicine journal (2024)
Asciminib is a novel allosteric STAMP (specifically targets the ABL myristoyl pocket) inhibitor of the BCR::ABL1 oncogene. Real-world clinical outcomes of patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic myeloid leukaemia (CML) in Australia on the Managed Access Programme for asciminib showed higher molecular responses for those with intolerance versus resistance ± intolerance to their last TKI. There remains a clinical need to improve outcomes in patients with CML who have resistance to multiple TKIs, especially in the ponatinib-pretreated cohort.
Keyphrases
- chronic myeloid leukemia
- tyrosine kinase
- end stage renal disease
- dendritic cells
- bone marrow
- newly diagnosed
- ejection fraction
- acute myeloid leukemia
- study protocol
- prognostic factors
- small molecule
- randomized controlled trial
- type diabetes
- acute lymphoblastic leukemia
- patient reported outcomes
- immune response
- insulin resistance
- single molecule